I'm not really one who looks for advice in most situations. I am quite confident in my abilities to figure things out using grey matter and resources readily available to people in this day and age. But thanks though.
I don't worry about the day to day fluctuations in this stock. I have been here for many years and have seen this drift down many times before. You were buying 30,000 shares soon after the raise. A small haircut right now, but if history repeats itself, we should hit the $1.20's if that happens, hopefully it was just a case of exaggerated bravado on the purchasing for your sake. But if you didn't actually pull the trigger and we hit the $1.20's, an advanced "your welcome." You claimed you've seen raises and prices go back up after with other companies. But you haven't watched this company long enough. I don't like to just sit back and relax. I like to think of potential scenarios etc to help me decide when or if to pull the trigger. Not that it's helped me in this stock, I begrudgingly admit.
But I do worry about dilution. This is what we have had of late.
January...12.2 million shares
Q3...4 million share gift to the twins
October...13.5 million shares and 830,000 from ATM
Grand total...29.7 million shares.
So for them to dilute shares by what, 30 to 35 percent this year alone is a concern to me. I would think it would be a concern for most. This dilution bought is approximately 5 quarters of keeping our lights on. Obviously necessary, but still a concern.
I will be my good old backseat CEO for a moment. Do you not think making a deal with larger pharma on one of our product candidates would have been a better route to go. Yes not a great deal like management may want, but one that enables us to have a substantial increase in non dilutive cash. Bow down and get a deal done closer on their terms. They're big dogs for a reason. Having a large pharma backing us, would bring instant credibility to this company. Would also bring about the vast knowledge and resources that come from this type of company, especially when it comes to clinical trials.
We do after all, have countless other indications that this technology may be able to help. Some argue that once a deal is done at a lower price, hard to move up. Don't think that's the case at all. Just the circumstance alone is easily justified. But if a company is offered something that will add to their bottom line, why would they refuse? If they do, others won't. Someone came up to me and offered me a percentage of profits that would give me 10, 20, 30 percent (whatever that number would be) I would be foolish not to at least take a serious look at it.
Now let's take a little closer look at these trade shows. What industry did Zami come from? Elbit vision systems. See this type of product makes sense for trade shows. You have a product you want to sell, show it to the masses in shows related to your product. Marketing for something to actually market.
Now the shows we go to what, give you 20 to 30 minutes to present your clinical trial advances, or the 3D bioreactor that you can't buy or use? Anyone watch one of Karine's presentations at one of these things? Yawn. Sorry don't see the value in it. But it seems that Zami sure does. That's where he came from, being able to come back standing tall and say we sold x amount of widgets. Don't think there is much value to any of this. Clinical trial results peak big pharma interest of the serious kind. Anyone who is interested in Pluristem's product, is already aware of anything anyone would say at one of these things. A simple phone call or a few clicks on the keyboard, and the doors are open.
I understand that this is the norm. Under normal circumstances I could justify it as a cost of doing business. A little marketing expense, to help with your name. But to be within 8 months of having the lights turn down, at least in 3/4 of the office while the cost cutting contingency plan comes into place, is unjustified beyond belief. This is where the appropriate jet setting stereotypical comment stem from. Lets book even more of them. Don't recall ever seeing so many as I have right now. Rubs shareholders the wrong way, wasteful use of existing, ever dwindling cash on hand.
So this product doesn't worry me in the least. Management is THE worry. Wrong people running this company, and pushing ever closer to the "year of the shareholder" being postponed for yet another year. If nothing happens by year end, heads should roll. And if nothing happens by year end, our price will be at a point where it might piss people off who have a voice to make it happen. Think I'm tough on management now? Trust me I will be relentless come the last trading day of 2017 and sitting in the $1.20's or lower.
Does anyone actually make it to the end of my posts? LMBO!!!
